CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages ...
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is positioned at the intersection of regenerative medicine and medical aesthetics. The company’s core differentiator is its proprietary, plant-based genetic engineering technology used to produce recombinant type I human collagen. This collagen platform is designed to enable advanced biomedical applications, most notably three-dimensional (3D) bioprinting ...CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is positioned at the intersection of regenerative medicine and medical aesthetics. The company’s core differentiator is its proprietary, plant-based genetic engineering technology used to produce recombinant type I human collagen. This collagen platform is designed to enable advanced biomedical applications, most notably three-dimensional (3D) bioprinting of soft tissues and, in targeted workflows, tissue/organ constructs for regenerative and translational research use.
From a product and services perspective, CollPlant develops and commercializes several categories of offerings. In the bioprinting and tissue fabrication area, it supplies BioInks engineered to support 3D tissue and organ fabrication, as well as regenerative soft-tissue matrices that are intended to provide structural and biological support in repair settings. For medical aesthetics and aesthetic soft-tissue correction, the company develops dermal and soft tissue fillers aimed at reducing wrinkles and related indications. The company also works on breast implant technologies, including approaches combining 3D-bioprinted components and injectable formats intended to support breast tissue regeneration.
CollPlant’s portfolio additionally includes specialized regenerative soft-tissue repair and wound-care matrices. Examples referenced in public descriptions include VergenixSTR (focused on soft tissue repair for tendinopathy) and VergenixFG (designed for wound care and deep surgical incision management, including conditions such as diabetic, venous, and pressure ulcers, as well as burns and bedsores).
In terms of commercial strategy and ecosystem partnerships, CollPlant maintains collaboration agreements with multiple partners spanning bioprinting platforms and research/clinical stakeholders. These include collaborations with organizations such as 3D Systems and Cellink, as well as research and development collaborations involving institutes and other companies, reflecting a go-to-market approach that leverages technology compatibility, distribution pathways, and co-development opportunities.
Cost and BOM (bill-of-materials) considerations are inherently tied to the use of plant-based recombinant collagen rather than traditional animal-derived or alternative collagen sources; however, specific unit economics and BOM are not detailed in the provided materials. Financially, the company has an identified market presence on NASDAQ Global Market with a relatively small workforce (about 39 employees reported), which is consistent with a biotech/regenerative-medicine model that relies heavily on R&D execution, clinical development programs, IP generation, and partner-led commercialization channels.
Key people include Yehiel Tal, who has served as Chief Executive Officer since January 2010 and joined the board in 2022. Founded in 2004 and headquartered in Rehovot, Israel, CollPlant continues to pursue regulatory and product-development milestones across regenerative repair and aesthetic medical applications, aiming to translate its collagen-bioprinting platform into practical therapies and products.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$2.4M
+360.4%
+21.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-11.5M
+30.8%
+3.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+26.3%
+106.3%
+42.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-484.3%
+85.5%
+18.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-484.6%
+85.0%
+20.6%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-9.4M
+35.2%
+5.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-398.4%
+85.9%
+22.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
46.8%
+104.5%
+15.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.53x
-43.1%
-10.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
